Newcells Biotech to develop 3D retinal organoids using hiPSC derived skin cells

Newcells Biotech in partnership with Newcastle University has been awarded further funding from the NC3R CRACK IT project to create 3D retinal organoids that more closely recapitulate the structure and function of the human retina, using hiPSCs which can be used for large scale disease modelling, toxicology and pharmacology screening to replace the use of animals in the discovery of new ophthalmic drugs.

In Phase 1, the team will generate 3D laminated human retinae containing all the major cell types that formed functional synapses, responded to light and electrophysiological stimuli, and accurately identified two compounds known to be toxic to the human retina. In Phase 2, the model will be developed further through incorporating microglia and adaption to rodent and primate derived iPSC, optimising the cryopreservation process to ensure the organoids are accessible worldwide and extending the compound screen to validate the model as a tool for efficacy and toxicity screening.

The development of drugs for eye disorders is a growing field with the market for therapies targeting retinal disorders expected to grow to $14.8 billion by 2022. There are no adequate in vitro models that recapitulate the complex structure of the mature human retina, therefore, the majority of efficacy and safety testing in ophthalmological drug development is currently performed in animals (rodents and rabbits). The project is sponsored by Merck, Novartis and Roche.

You might also be interested in…

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication.  Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping

The Biosphere

Newcells Biotech scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.    The purpose-built space in the city centre site

COVID-19 Vaccine

An Overview of Vaccine Development & Sub-Types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination